首页> 外文期刊>Clinical ophthalmology >Pars plana vitrectomy combined with internal limiting membrane peeling for recurrent macular edema due to branch retinal vein occlusion after antivascular endothelial growth factor treatments
【24h】

Pars plana vitrectomy combined with internal limiting membrane peeling for recurrent macular edema due to branch retinal vein occlusion after antivascular endothelial growth factor treatments

机译:玻璃体腔切除术联合内部限制膜剥离术治疗抗血管内皮生长因子后视网膜分支支静脉阻塞导致黄斑水肿复发

获取原文
           

摘要

Purpose: To evaluate the anatomic and functional outcomes of pars plana vitrectomy combined with internal limiting membrane peeling for recurrent macular edema (ME) due to branch retinal vein occlusion (BRVO) after intravitreal injections of antivascular endothelial growth factor (anti-VEGF) agents. Methods: Twenty-four eyes of 24 patients with treatment-naive ME from BRVO were treated with intravitreal injections of anti-VEGF agents. Recurred ME was treated with pars plana vitrectomy combined with internal limiting membrane peeling. Results: After the surgery, ME was significantly reduced at 1?month ( P =0.031) and the reduction increased with time ( P =0.007 at the final visit). With the reduction in ME, treated eyes showed a slow improvement in visual acuity (VA). At the final visit, improvement in VA was statistically significant compared with baseline ( P =0.048). The initial presence of cystoid spaces, serous retinal detachment, or subretinal hemorrhage under the fovea, as well as retinal perfusion status, showed no association with VA improvement. However, the presence of epiretinal membrane showed a significant association with the visual recovery. Although eyes without epiretinal membrane showed visual improvement (-0.10±0.32 in logarithm of the minimum angle of resolution [logMAR]), eyes with epiretinal membrane showed greater visual improvement (-0.38±0.12 in logMAR, P =0.012). Conclusion: For recurrent ME due to BRVO after anti-VEGF treatment, particularly when accompanied by epiretinal membrane, pars plana vitrectomy combined with internal limiting membrane peeling might be a possible treatment option.
机译:目的:评估玻璃体腔内注射抗血管内皮生长因子(anti-VEGF)药物后因分支视网膜静脉闭塞(BRVO)而引起的复发性黄斑水肿(ME),联合平板内玻璃体切除术的解剖学和功能结局。方法:对24例原发性BRVO初治ME患者的24只眼进行玻璃体内注射抗VEGF药物治疗。复发的ME采用平面内玻璃体切除术结合内部限膜剥离治疗。结果:手术后,ME在1个月时显着降低(P = 0.031),并且随着时间的推移而降低(最后一次访视P = 0.007)。随着ME的降低,治疗的眼睛显示出视力(VA)的缓慢改善。在最后一次就诊时,与基线相比,VA的改善具有统计学意义(P = 0.048)。中央凹下囊样间隙的最初存在,浆液性视网膜脱离或视网膜下出血以及视网膜灌注状态均未显示与VA改善相关。但是,视网膜前膜的存在与视觉恢复显着相关。尽管没有视网膜前膜的眼显示出视觉改善(最小分辨角[logMAR]的对数为-0.10±0.32),但是具有视网膜前膜的眼显示出更大的视觉改善(logMAR为-0.38±0.12,P = 0.012)。结论:对于抗VEGF治疗后因BRVO引起的ME复发,特别是伴有视网膜前膜时,平面玻璃体切除联合内部限制膜剥离可能是一种治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号